GSK and Vir, navigating early antibody pitfalls, tout delta variant-busting data for latecomer sotrovimab Abbott’s rapid antigen COVID-19 test cleared in Europe for at-home, direct-to-consumer sales Aetna Foundation, U.S. News report: Healthiest communities tend to be less COVID vaccine hesitant Sanofi commits $476M a year to mRNA vaccine center in race to expand tech beyond COVID-19 Foresite’s 2nd SPAC deal counts Gilead as an investor in $276M bid for COVID-19 biotech Pardes Hospitals, corporations own nearly half of medical practices, spurred by COVID-19 disruption: report COVID-19 tracker: Heart inflammation cases 'higher than expected' after jab, study says; Delta variant sparks concerns in LA Physician productivity, revenues rebounding to pre-pandemic levels: report WPP adds chief strategy officer at VMLY&Rx to helm new practice in post-pandemic era Featured Story | By Fraiser Kansteiner While several vaccines now stand tall in the fight against COVID-19, therapies—and antibody drugs in particular—have had a decidedly tougher time. Saddled with access issues and beset by fast-emerging variants, firstcomer Eli Lilly has recently been forced to re-think its tactics. Now, GlaxoSmithKline and Vir Biotechnology are applying those lessons to their solo agent sotrovimab. read more |
| |
|---|
|
| | Webinar: New Trends in Virtual Trials Monday, July 26 | 11am ET / 8am PT Last year, clinical trial platform developer Medable raised $91M in private funding, amid the COVID-19 pandemic that touched off huge demand among pharma companies looking to initiate “siteless” or virtual clinical trials. Explore the role of CROs in siteless trials and the opportunities and challenges for CROs to expand their capabilities in this burgeoning area. Register now. |
Top Stories By Andrea Park The new CE mark allows the at-home test to be sold directly to European consumers, regardless of whether they’re showing any COVID symptoms. read more By Paige Minemyer The country's healthiest communities also tend to be less hesitant to get vaccinated for COVID-19, according to a new study. read more By Nick Paul Taylor Sanofi is set to invest €400 million ($476 million) a year in a dedicated vaccines mRNA Center of Excellence. The commitment is intended to establish Sanofi as a frontrunner in the race to develop mRNA vaccines against a wide range of infectious diseases. read more By Amirah Al Idrus Foresite Capital’s second special purpose acquisition company (SPAC) has landed on its target: Pardes Biosciences, a biotech working on antiviral treatments for COVID-19. Through the merger, Pardes will add about $276 million to the bank, which will get its lead candidate into the clinic later this year. read more By Dave Muoio As of January 1, 2021, nearly half of all U.S. practices were owned by hospitals or corporate entities while seven in 10 physicians were employed by these organizations, according to data from the Physicians Advocacy Institute. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner A new study published in JAMA found "higher than expected" rates of heart inflammation among U.S. military members following an mRNA jab, although the cases are still considered rare. L.A. County health officials are concerned about the rapid spread of the Delta variant and are asking all residents to mask while inside. And more. read more By Heather Landi After a year of significant disruption, U.S. physician groups are starting to see signs of financial recovery. Physician groups across the country continued to see key performance metrics return to near pre-pandemic levels in the first quarter of 2021, suggesting an end to the volatility driven by COVID-19 that rocked practices throughout 2020, according to a new report from Kaufman Hall. read more By Beth Snyder Bulik WPP’s new chief strategy officer at its prescription drug-focused agency VMLY&Rx, Nichole Davis, is sailing the new practice through a pharma and biotech drug world dramatically changed by the COVID-19 pandemic. read more | | Webinar: COVID-19 Virus Sequencing for Drug Development Wednesday, July 28 | 10:30am ET / 7:30am PT As new COVID-19 variants continue to emerge, virus sequencing will play critical and ongoing role in drug and vaccine development. This webinar will connect insights from population surveillance to potential solutions for drug developers, outline approaches to COVID-19 virus sequencing and more. Register Now. |
|
